1. Introduction {#s0005}
===============

Percutaneous coronary intervention (PCI) is currently an effective method ([@b0035]) used in clinical treatment of acute myocardial infarction (see [Fig. 1](#f0005){ref-type="fig"}). Scientific and effective antiplatelet therapy can significantly reduce the incidence of myocardial ischemia and inner frame thrombosis and other adverse events in patients (see [Fig. 2](#f0010){ref-type="fig"}) undergoing percutaneous coronary intervention (PCI). This study analyzed the antiplatelet therapeutic effect of ticagrelor vs clopidogrel for acute myocardial infarction patients undergoing percutaneous coronary intervention (PCI).Fig. 1Schematic diagram of acute myocardial infarction.Fig. 2Schematic diagram of PCI.

2. Materials and methods {#s0010}
========================

2.1. General reference {#s0015}
----------------------

2000 patients who had been treated by undergoing percutaneous coronary intervention in our hospital from January 2013 to December 2015 were selected as research objects. To reduce the formation of acute stent thrombosis caused by clopidogrel resistance, we had two options, one was to double the dosage of clopidogrel, and the other was to substitute ticagrelor for clopidogrel. Among the 2000 patients, 1100 were male patients, 900 were female patients. Their age ranged from 62 to 78, with average age of (68.34 ± 6.34). Based on random number table method, the 2000 patients were divided into experimental group and control group, each containing 1,000 patients.

The experimental group included 550 male patients and 450 female patients, with age ranging from 62 to 78, with average value at (60.51 ± 9.45). Complicating diseases in experiment group included 270 cases of hypertension, 220 cases of diabetes, 210 cases of hyperlipidemia; platelet aggregation rate wass (58.04 ± 5.61). By comparing the general information of experimental group and control group, we can find that there were no significant differences in case numbers, gender, age, other associated diseases, and platelet aggregation rate. Statistical analysis showed that P was greater than 0.05, therefore both groups can be observed as controlled trials.

2.2. Including criteria {#s0020}
-----------------------

The criteria of clopidogrel resistance: the change rate of ADP-induced platelet aggregation is less than 30% or over 70% ([@b0040]). The patients who were excluded include: patients who were administered with warfarin, dipyridamole, and cilostazol simultaneously; patients with neoplastic disease; patients with autoimmune disease; patients whose hepatic and renal functions were damaged; patients with history of cerebral hemorrhage; patients with other serious disease and expected lifetime was less than 1 year ([@b0050]).

2.3. Treatment method {#s0025}
---------------------

Patients in both groups took 300 mg of aspirin orally and were administered with 100U/kg heparin before PCI. After PCI, both groups took 100 mg aspirin once a day ([@b0020]).(1).Experimental group

The patients in experimental group took 180 mg ticagrelor before PCI and 90 mg ticagrelor twice a day after PCI ([@b0025]).(2).Control group

The patients in control group took 600 mg clopidogrel before PCI and 150 mg clopidogrel once a day.

Curative effect of both groups was assessed after 7-day of medicine administration. Relevant data of both groups were recorded in detail.

2.4. Observation methods {#s0030}
------------------------

Both groups were drawn 2.7 ml of fasting venous blood for platelet monitoring before PCI and 2 h, 24 h, 7 days after PCI respectively. Turbidimetric method was used to measure the ADP-induced platelet aggregation rate (see [Fig. 3](#f0015){ref-type="fig"}) and observe the change of platelet aggregation rate and success rate (The rate of 5 μmol/L ADP-induced platelet aggregation was less than 50%). Incidence of liver and kidney malfunction and adverse actions were also monitored ([@b0045]). All Patients accepted 6-month follow-up examination to record the incidences of major adverse cardiac and cerebrovascular events and the differences of indexes between two groups were compared.Fig. 3Platelet aggregation.

2.5. Statistical method {#s0035}
-----------------------

The SPSS19.0 statistical analysis software was used in the retrospective analysis. All data generated in the analysis were analyzed and processed by this software. Enumeration data were expressed in the form of ($\bar{x}$ ± s) and inter-group difference was compared by chi-square; measurement data was expressed by natural number and (n) and percentage (%) and the inter-group difference was compared by t. When P \< .05, the inter-group difference is regarded significant and of statistical significance.

3. Results {#s0040}
==========

3.1. Platelet aggregation rate {#s0045}
------------------------------

The platelet aggregation rate of experimental group before PCI and 2 h, 24 h, 7 days after PCI was 59.71% ± 7.24%, 59.20% ± 7.70%, 48.66% ± 7.80% and 43.39% ± 8.28%; The control group was 58.04% ± 5.61%, 56.25% ± 6.02%, 55.68% ± 3.14%, 53.94% ± 5.30%; Comparing the platelet aggregation rate between both groups, the inter-group difference was of statistical significance (P \< .05). The success rates of platelet aggregations of experimental group and control group were 80.56% and 46.86%, respectively. There were significant differences between the two groups and the difference was of statistical significance (P \< .05).

3.2. Other evaluating indicator {#s0050}
-------------------------------

The postoperative serum creatinine level of experimental group was higher than that in the control group (P \< .05). The incidence of adverse reactions in the experimental group was significantly lower than that of the control group, and the intergroup difference was of statistical significance (P \< .05). According to the results of 5-month follow-up examination of both groups, the incidence of major adverse cardiac and cerebrovascular events in experimental group was 5.20% (52/21,000) ,while the control group was 26.00% (260/1000) . It can be known that there were significant differences between the two groups and the intergroup difference was of statistical significance (P \< .05).

4. Discussions {#s0055}
==============

In the long-term antiplatelet therapy after percutaneous coronary intervention, clopidogrel and aspirin are two common drugs ([@b0005]). Under conventional percutaneous coronary intervention with clopidogrel, some patients may still suffer arterial thrombosis event, which is clinically named as clopidogrel resistance. Clopidogrel resistance severely impairs the clinical effect of percutaneous coronary intervention (PCI). It also increases the cost of treatment and the patient\'s pain. Clinical personnel should actively look for solutions to improve the effectiveness and safety of PCI clinical treatment. Ticagrelor is a novel platelet P2Y12 receptor antagonist, which is capable of reversibly binding P2Y12 receptor. So it could play a role in inhibiting ADP-inducing platelet activation by adjusting its structure ([@b0010]).

From the results above, we can see that the antiplatelet therapy effect of experimental group is superior to that of control group. So, compared with clopidogrel, ticagrelor has better antiplatelet therapy effect for patients with acute myocardial infarction undergoing percutaneous coronary intervention PCI). It could effectively reduce the incidence of postoperative adverse cardiac and cerebrovascular events and control the rate of adverse reactions within the acceptable range ([@b0015], [@b0030]).
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